PF04518600
Phase 3Small molecule
PfizerPF04518600 is one of 50 small molecule programs targeting Advanced Malignancies. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
201 competitors in Follicular Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Fludara
SanofiPhase 3
Zydelig
GileadPhase 3
Rayos
RRoxane Laboratories
Phase 3
Kesimpta
NovartisPhase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Tazverik
EEpizyme, Inc.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Copiktra
SSecuraBio
Phase 3
Mabthera
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Follicular Lymphoma1 trial
Rituximab + Immunotherapy in Follicular Lymphoma
Terminated·—·Phase 1·NCT03636503·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF04518600. EMBL-EBI & Wellcome Sanger Institute.
- [4]